SpringWorks Therapeutics, Inc (SWTX): Long-Term Debt to Capital Ratio

The price evolution data for SpringWorks Therapeutics (SWTX) reflects the dynamics of a biotech company rolling out sales of its first oncology drug supported by joint research with pharma behemoths. Growth is driven by the success of Ogsiveo and the potential of mirdametinib, bringing the metric to 0.01. However, financial stability is undermined by uncertainty regarding clinical trial results for rare pathologies, dependence on FDA verdicts, and the risk of underestimated market demand.

Fundamental asset screening requires an accurate assessment of the issuer's credit burden. This indicator compares liabilities with maturities exceeding one year against the company's total equity. By analyzing the long-term debt-to-equity trend, an investor determines the business's degree of reliance on borrowed funds. A low debt load is critical for SpringWorks Therapeutics (SWTX), as it ensures financial stability during the commercial launch of Ogsiveo and the development of new targeted oncology drugs.